Holen Sie sich die Stockscreener-App
1.65
3.12%
0.05
Handel nachbörslich:
1.65
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.60
Offen:
$1.6
24-Stunden-Volumen:
1.59M
Relative Volume:
0.62
Marktkapitalisierung:
$732.77M
Einnahmen:
$49.80M
Nettoeinkommen (Verlust:
$-50.34M
KGV:
-11.89
EPS:
-0.1388
Netto-Cashflow:
$-67.85M
1W Leistung:
-0.60%
1M Leistung:
+3.77%
6M Leistung:
+19.57%
1J Leistung:
+129.17%
1-Tages-Spanne:
$1.565
$1.65
1-Wochen-Bereich:
$1.55
$1.665
52-Wochen-Spanne:
$0.5137
$1.95
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.65 | 710.56M | 49.80M | -50.34M | -67.85M | -0.1388 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon secures $100m loan facility with Hercules Capital - Investing.com UK
Lexicon secures $100m loan facility with Hercules Capital By Investing.com - Investing.com South Africa
[Form 4] LEXICON PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Lexicon Pharmaceuticals (LXRX) director receives new option and RSU awards - Stock Titan
Lexicon (NASDAQ: LXRX) director awarded stock options and 35,714 RSUs - Stock Titan
Lexicon Pharmaceuticals (LXRX) director receives new options and RSUs - Stock Titan
Lexicon Pharmaceuticals (NASDAQ: LXRX) director receives new option and RSU awards - Stock Titan
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital - The Manila Times
Lexicon Pharmaceuticals (LXRX) director receives new option and RSU grants - Stock Titan
Lexicon Pharmaceuticals secures $100 million loan facility with Hercules Capital - StreetInsider
$55M upfront helps Lexicon repay debt under new $100M loan - Stock Titan
Earnings call transcript: Lexicon Pharmaceuticals beats Q4 2025 expectations - Investing.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday - MarketBeat
Earnings Preview: LXRX to Report Financial Results Pre-market on May 07 - Moomoo
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851 - Insider Monkey
Lexicon Pharmaceuticals | 8-K: Current report - Moomoo
Lexicon (NASDAQ: LXRX) expands share pools and converts Series B preferred - Stock Titan
Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN
Lexicon schedules May 7 webcast to discuss its Q1 results - Stock Titan
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - The Manila Times
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
LXRX Stock Chart | LEXICON PHARMACEUTICALS INC (NASDAQ:LXRX) - ChartMill
How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851 - Yahoo Finance
Lexicon reports FDA's decision to extend review period for Zynquista - MSN
Lexicon’s Stock Ran On Partnerships, Not INPEFA Sales - Finimize
Lexicon Pharmaceuticals Moves Pilavapadin to Phase 3 Development - HarianBasis.co
Lexicon Pharmaceuticals presents Phase 2b results supporting 10 mg dose in DPNP at AAN 2026 - Traders Union
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data - Insider Monkey
LXRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SONATA-HCM Phase 3 clinical trial accelerates HCM drug research for Lexicon Pharmaceuticals - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 earnings call transcript - MSN
Significant First Quarter Growth for LXRX Driven by New Client R - GuruFocus
Lexicon (LXRX) Advances Pilavapadin After Positive Phase 2b Stud - GuruFocus
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting - The Manila Times
New Lexicon data back a 10 mg diabetic nerve pain dose for Phase 3 - Stock Titan
Lexicon Pharmaceuticals (LXRX) Stock Weekly Analysis (Smart Money Outflows) 2026-04-16Community Pattern Alerts - Cổng thông tin điện tử Tỉnh Sơn La
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year HighHere's Why - MarketBeat
How does macroeconomics affect Lexicon Pharmaceuticals (LXRX) Stock | LXRX Q4 Earnings: Beats Estimates by $0.03Regulatory Risk - Cổng thông tin điện tử tỉnh Lào Cai
Lexicon Pharmaceuticals Q2 2025 Earnings Preview - MSN
Growth Report: What is the target price for Lexicon Pharmaceuticals Inc stock2026 Update & Weekly High Return Opportunities - baoquankhu1.vn
IPO Launch: Is Lexicon Pharmaceuticals Inc stock trending bullish2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
LXRX SEC FilingsLexicon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week HighShould You Buy? - MarketBeat
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):